Compare Stocks: FHTX, VALN, DMAC, and FTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMAC DiaMedica Therapeutics	$10.77 +7.7%	$7.81	$5.24 ▼ $11.00	$539.26M	0.95	218,494 shs	409,079 shs
FHTX Foghorn Therapeutics	$2.10 -1.4%	$3.31	$1.79 ▼ $7.61	$126.49M	3.22	669,795 shs	673,575 shs
FTH Sensei Biotherapeutics	$19.99 +1.7%	$27.95	$7.45 ▼ $42.14	$507.76M	-0.15	372,270 shs	236,011 shs
VALN Valneva	$5.63 +2.2%	$6.10	$4.75 ▼ $12.18	$522.82M	1.37	19,223 shs	6,670 shs

7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMAC DiaMedica Therapeutics	+7.70%	+9.67%	+27.91%	+59.08%	+60.51%
FHTX Foghorn Therapeutics	-1.41%	-1.41%	+5.00%	-62.30%	-40.51%
FTH Sensei Biotherapeutics	+1.73%	+4.11%	-26.24%	-18.34%	+1,998,999,900.00%
VALN Valneva	+2.18%	-1.92%	-3.26%	+8.69%	-38.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMAC DiaMedica Therapeutics	$10.77 +7.7%	$7.81	$5.24 ▼ $11.00	$539.26M	0.95	218,494 shs	409,079 shs
FHTX Foghorn Therapeutics	$2.10 -1.4%	$3.31	$1.79 ▼ $7.61	$126.49M	3.22	669,795 shs	673,575 shs
FTH Sensei Biotherapeutics	$19.99 +1.7%	$27.95	$7.45 ▼ $42.14	$507.76M	-0.15	372,270 shs	236,011 shs
VALN Valneva	$5.63 +2.2%	$6.10	$4.75 ▼ $12.18	$522.82M	1.37	19,223 shs	6,670 shs

7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMAC DiaMedica Therapeutics	+7.70%	+9.67%	+27.91%	+59.08%	+60.51%
FHTX Foghorn Therapeutics	-1.41%	-1.41%	+5.00%	-62.30%	-40.51%
FTH Sensei Biotherapeutics	+1.73%	+4.11%	-26.24%	-18.34%	+1,998,999,900.00%
VALN Valneva	+2.18%	-1.92%	-3.26%	+8.69%	-38.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMAC DiaMedica Therapeutics	2.50	Moderate Buy	$12.00	11.42% Upside
FHTX Foghorn Therapeutics	2.27	Hold	$6.14	192.52% Upside
FTH Sensei Biotherapeutics	2.94	Moderate Buy	$56.17	180.97% Upside
VALN Valneva	1.67	Reduce	$9.30	65.19% Upside

Current Analyst Ratings Breakdown

Latest FHTX, VALN, DMAC, and FTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/4/2026	FTH Sensei Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$70.00 ➝ $69.00
10/27/2026	FTH Sensei Biotherapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$55.00
10/16/2026	FTH Sensei Biotherapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	DMAC DiaMedica Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	FHTX Foghorn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	FTH Sensei Biotherapeutics	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/13/2026	FHTX Foghorn Therapeutics	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ In-Line	$3.00
10/13/2026	FHTX Foghorn Therapeutics	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Hold	$3.00
10/2/2026	FHTX Foghorn Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$12.00 ➝ $5.00
10/2/2026	FHTX Foghorn Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $2.00
10/2/2026	FHTX Foghorn Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$12.00 ➝ $5.00

(Data available from 11/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.08 per share	N/A
FHTX Foghorn Therapeutics	$30.91M	4.03	N/A	N/A	($1.92) per share	-1.09
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$14.74 per share	N/A
VALN Valneva	$197.56M	2.70	N/A	N/A	$1.39 per share	4.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMAC DiaMedica Therapeutics	-$32.77M	-$0.72	N/A	N/A	N/A	N/A	-77.76%	-69.43%	11/11/2026 (Estimated)
FHTX Foghorn Therapeutics	-$74.28M	-$0.98	N/A	N/A	N/A	-175.78%	N/A	-31.17%	N/A
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,168.50%	-151.84%	N/A
VALN Valneva	-$130.33M	-$2.11	N/A	12.80	N/A	-110.33%	-153.20%	-39.50%	11/19/2026 (Estimated)

Latest FHTX, VALN, DMAC, and FTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/19/2026	Q3 2026	VALN Valneva	-$0.23	N/A	N/A	N/A	$43.67 million	N/A
11/11/2026	Q3 2026	DMAC DiaMedica Therapeutics	-$0.20	N/A	N/A	N/A	$13.50 million	N/A
11/3/2026	Q3 2026	FTH Sensei Biotherapeutics	-$0.66	-$0.79	-$0.13	-$0.7890	N/A	N/A
8/14/2026	Q2 2026	VALN Valneva	-$0.1886	-$0.40	-$0.2114	-$0.38	$44.17 million	$39.37 million
8/10/2026	Q2 2026	DMAC DiaMedica Therapeutics	-$0.2009	-$0.19	+$0.0109	-$0.19	$13.50 million	N/A
8/6/2026	Q2 2026	FHTX Foghorn Therapeutics	-$0.2450	-$0.10	+$0.1450	-$0.10	$6.81 million	$16.07 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMAC DiaMedica Therapeutics	N/A	6.72	6.72
FHTX Foghorn Therapeutics	N/A	3.36	3.36
FTH Sensei Biotherapeutics	N/A	19.69	19.69
VALN Valneva	2.04	2.16	1.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DMAC DiaMedica Therapeutics	10.12%
FHTX Foghorn Therapeutics	61.55%
FTH Sensei Biotherapeutics	10.50%
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
DMAC DiaMedica Therapeutics	5.00%
FHTX Foghorn Therapeutics	9.02%
FTH Sensei Biotherapeutics	7.00%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DMAC DiaMedica Therapeutics	35	53.93 million	51.23 million	Optionable
FHTX Foghorn Therapeutics	106	59.38 million	54.03 million	Optionable
FTH Sensei Biotherapeutics	29	25.84 million	24.03 million	Not Optionable
VALN Valneva	674	94.89 million	80.74 million	Not Optionable

FHTX, VALN, DMAC, and FTH Headlines

Recent News About These Companies

Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026

November 4 at 11:45 AM | globenewswire.com

Valneva (NASDAQ:VALN) Shares Gap Down - Time to Sell?

November 2 at 11:59 AM | marketbeat.com

Valneva's Lyme Data Land With a Thud as Goldman Trims Its Enthusiasm to a Nudge

October 29, 2026 | ad-hoc-news.deA

Contrasting Valneva (NASDAQ:VALN) & Atara Biotherapeutics (NASDAQ:ATRA)

October 27, 2026 | americanbankingnews.com

Valneva Draws a Line Between a Closed UK File and an Open Lyme Timeline

October 22, 2026 | ad-hoc-news.deA

MHRA revokes approval for Valneva’s Ixchiq due to safety frailties

October 21, 2026 | yahoo.com

Valneva Lines Up Four-Week Investor Push as Pfizer Prepares to Unveil VALOR Lyme Data

October 15, 2026 | ad-hoc-news.deA

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

October 14, 2026 | globenewswire.com

Valneva SE Provides Update On IXCHIQ In The United Kingdom

October 9, 2026 | marketscreener.comM

Valneva Drops UK Appeal as Analysts Keep Faith in Lyme Pipeline

October 9, 2026 | ad-hoc-news.deA

Valneva Shares Fall as UK Withdraws Approval for Ixchiq Chikungunya Vaccine

October 8, 2026 | finance.yahoo.com

Valneva Says UK Revokes Chikungunya Virus Vaccine's Marketing Authorization; Shares Down Pre-Bell

October 8, 2026 | finance.yahoo.com

Valneva: United Kingdom Withdraws IXCHIQ Authorization

October 8, 2026 | marketscreener.comM

Valneva ADRs fall as UK revokes IXCHIQ marketing authorization

October 8, 2026 | finance.yahoo.com

UK Revokes Marketing Authorisation For Valneva's Chikungunya Vaccine IXCHIQ; Shares Slide

October 8, 2026 | rttnews.com

Valneva Says Ixchiq Vaccine Recalled in U.K. Due to Safety Concerns

October 7, 2026 | marketwatch.com

VALN stock plunges 7% after-hours as UK revokes Valneva’s IXCHIQ authorization in latest market setback

October 7, 2026 | msn.com

Valneva Provides Update on IXCHIQ® in the United Kingdom

October 7, 2026 | globenewswire.com

Journée en forte hausse pour Valneva SE

September 28, 2026 | boursier.comB

Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)

September 24, 2026 | defenseworld.netD

Football fundraiser collects £2k for Livingston charity Team Jak Foundation

September 22, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX, VALN, DMAC, and FTH Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

$10.77 +0.77 (+7.70%)

Closing price 11/4/2026 04:00 PM Eastern

Extended Trading

$10.66 -0.12 (-1.07%)

As of 06:56 AM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Foghorn Therapeutics NASDAQ:FHTX

$2.10 -0.03 (-1.41%)

Closing price 11/4/2026 04:00 PM Eastern

Extended Trading

$2.10 +0.00 (+0.24%)

As of 11/4/2026 05:28 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sensei Biotherapeutics NASDAQ:FTH

$19.99 +0.34 (+1.73%)

Closing price 11/4/2026 04:00 PM Eastern

Extended Trading

$19.74 -0.25 (-1.25%)

As of 11/4/2026 07:30 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Valneva NASDAQ:VALN

$5.63 +0.12 (+2.18%)

Closing price 11/4/2026 04:00 PM Eastern

Extended Trading

$5.80 +0.17 (+2.93%)

As of 04:05 AM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FHTX, VALN, DMAC, and FTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FHTX, VALN, DMAC, and FTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FHTX, VALN, DMAC, and FTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX, VALN, DMAC, and FTH Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

Foghorn Therapeutics NASDAQ:FHTX

Sensei Biotherapeutics NASDAQ:FTH

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FHTX, VALN, DMAC, and FTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FHTX, VALN, DMAC, and FTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FHTX, VALN, DMAC, and FTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX, VALN, DMAC, and FTH Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

Foghorn Therapeutics NASDAQ:FHTX

Sensei Biotherapeutics NASDAQ:FTH

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools